Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis

References

• Abush H, Ghose S, Van Enkevort EA, Clementz BA, Pearlson GD, Sweeney JA, Keshavan MS, Tamminga CA, Ivleva EI. 2018. Associations between adolescent cannabis use and brain structure in psychosis. Psychiatry Res Neuroimaging. 276:53–64.
   PubMed Web of Science ®Google Scholar
• Adamson SJ, Kay-Lambkin FJ, Baker AL, Lewin TJ, Thornton L, Kelly BJ, Sellman JD. 2010. An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Drug Alcohol Depend. 110(1–2):137–143.
   PubMed Web of Science ®Google Scholar
• Adan A, Arredondo AY, del Mar Capella M, Prat G, Forero DA, Navarro JF. 2017. Neurobiological underpinnings and modulating factors in schizophrenia spectrum disorders with a comorbid substance use disorder: a systematic review. Neurosci Biobehav Rev. 75:361–377.
   PubMed Web of Science ®Google Scholar
• Agrawal A, Lynskey MT. 2006. Jun) The genetic epidemiology of cannabis use, abuse and dependence. Addiction. 101(6):801–812.
   PubMed Web of Science ®Google Scholar
• Agrawal A, Lynskey MT. 2014. Cannabis controversies: how genetics can inform the study of comorbidity. Addiction. 109(3):360–370.
   PubMed Web of Science ®Google Scholar
• Appiah-Kusi E, Petros N, Wilson R, Colizzi M, Bossong MG, Valmaggia L, Mondelli V, McGuire P, Bhattacharyya S. 2020a. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology. 237(4):1121–1130.
   PubMed Web of Science ®Google Scholar
• Appiah-Kusi E, Wilson R, Colizzi M, Foglia E, Klamerus E, Caldwell A, Bossong MG, McGuire P, Bhattacharyya S. 2020b. Childhood trauma and being at-risk for psychosis are associated with higher peripheral endocannabinoids. Psychol Med. 50(11):1862–1871.
   PubMed Web of Science ®Google Scholar
• Arsalan A, Iqbal Z, Tariq M, Ayonrinde O, Vincent JB, Ayub M. 2019. Association of smoked cannabis with treatment resistance in schizophrenia. Psychiatry Res. 278:242–247.
   PubMed Web of Science ®Google Scholar
• Atwood BK, Mackie K. 2010. Jun) CB2: a cannabinoid receptor with an identity crisis [Research Support, N.I.H., Extramural Review]. Br J Pharmacol. 160(3):467–479.
   PubMed Web of Science ®Google Scholar
• Babor T, Caetano R, Casswell S, Edwards G, Giesbrecht N, Graham K, Grube J, Gruenewald P, Hill L, Holder H. 2010. Alcohol: no ordinary commodity: research and public policy. Rev Bras Psiquiatr. 26(4):280–283.
   Google Scholar
• Barkus E, Lewis S. 2008. Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychol Med. 38(9):1267–1276.
   PubMed Web of Science ®Google Scholar
• Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O'Brien R, Schofield N, McGovern J. 2001. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry. 158(10):1706–1713.
   PubMed Web of Science ®Google Scholar
• Barrowclough C, Marshall M, Gregg L, Fitzsimmons M, Tomenson B, Warburton J, Lobban F. 2014. A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis: a randomized controlled trial. Psychol Med. 44(13):2749–2761.
   PubMed Web of Science ®Google Scholar
• Beale C, Broyd SJ, Chye Y, Suo C, Schira M, Galettis P, Martin JH, Yücel M, Solowij N. 2018. Prolonged cannabidiol treatment effects on hippocampal subfield volumes in current cannabis users. Cannabis Cannabinoid Res. 3(1):94–107.
   PubMedGoogle Scholar
• Bechtold J, Simpson T, White HR, Pardini D. 2015. Chronic adolescent marijuana use as a risk factor for physical and mental health problems in young adult men. Psychol Addict Behav. 29(3):552–563.
   PubMed Web of Science ®Google Scholar
• Bioque M, García-Bueno B, Macdowell KS, Meseguer A, Saiz PA, Parellada M, Gonzalez-Pinto A, Rodriguez-Jimenez R, Lobo A, Leza JC, et al. 2013. Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacology. 38(13):2568–2577.
   PubMed Web of Science ®Google Scholar
• Bloomfield MA, Mouchlianitis E, Morgan CJ, Freeman TP, Curran HV, Roiser JP, Howes OD. 2016. Salience attribution and its relationship to cannabis-induced psychotic symptoms. Psychol Med. 46(16):3383–3395.
   PubMed Web of Science ®Google Scholar
• Borgan F, Kokkinou M, Howes O. 2021. The cannabinoid CB1 receptor in schizophrenia. Biol Psychiatry Cogn Neurosci Neuroimaging. 6(6):646–659.
   PubMedGoogle Scholar
• Borgan F, Beck K, Butler E, McCutcheon R, Veronese M, Vernon A, Howes OD. 2019a. The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species. Psychopharmacology. 236(11):3257–3270.
   PubMed Web of Science ®Google Scholar
• Borgan F, Laurikainen H, Veronese M, Marques TR, Haaparanta-Solin M, Solin O, Dahoun T, Rogdaki M, Salokangas RKR, Karukivi M, et al. 2019b. Cannabinoid 1 receptor levels and cognition in patients with first episode psychosis: a positron emission tomography study in two independent cohorts of patients. JAMA Psychiatry. 76(10):1074.
   PubMedGoogle Scholar
• Borgan F, O’Daly O, Veronese M, Marques TR, Laurikainen H, Hietala J, Howes O. 2019c. The neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI study. Mol Psychiatry. :1–11.
   Web of Science ®Google Scholar
• Borgan FR, Jauhar S, McCutcheon RA, Pepper FS, Rogdaki M, Lythgoe DJ, Howes OD. 2019d. Glutamate levels in the anterior cingulate cortex in un-medicated first episode psychosis: a proton magnetic resonance spectroscopy study. Sci Rep. 9(1):1–10.
   PubMedGoogle Scholar
• Bossong MG, Kahn RS. 2016. The salience of reward. JAMA Psychiatry. 73(8):777–778.
   PubMed Web of Science ®Google Scholar
• Brunette MF, Dawson R, O’Keefe CD, Narasimhan M, Noordsy DL, Wojcik J, Green AI. 2011. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagnosis. 7(1–2):50–63.
   PubMed Web of Science ®Google Scholar
• Buchy L, Mathalon DH, Cannon TD, Cadenhead KS, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, et al. 2016. Relation between cannabis use and subcortical volumes in people at clinical high risk of psychosis. Psychiatry Res Neuroimaging. 254:3–9.
   PubMed Web of Science ®Google Scholar
• Burggren AC, Siddarth P, Mahmood Z, London ED, Harrison TM, Merrill DA, Small GW, Bookheimer SY. 2018. Subregional hippocampal thickness abnormalities in older adults with a history of heavy cannabis use. Cannabis Cannabinoid Res. 3(1):242–251.
   PubMedGoogle Scholar
• Cardno AG, Marshall EJ, Coid B, Macdonald AM, Ribchester TR, Davies NJ, Venturi P, Jones LA, Lewis SW, Sham PC, et al. 1999. Heritability estimates for psychotic disorders. Arch Gen Psychiatry. 56(2):162.
   PubMed Web of Science ®Google Scholar
• Carliner H, Brown QL, Sarvet AL, Hasin DS. 2017. Cannabis use, attitudes, and legal status in the U.S.: A review. Prev Med. 104:13–23.
   PubMed Web of Science ®Google Scholar
• Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, et al. 2005. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the Catechol-O-Methyltransferase gene: longitudinal evidence of a Gene X environment interaction. Biol Psychiatry. 57(10):1117–1127.
   PubMed Web of Science ®Google Scholar
• Ceccarini J, Casteels C, Koole M, Bormans G, Van Laere K. 2013. Transient changes in the endocannabinoid system after acute and chronic ethanol exposure and abstinence in the rat: a combined PET and microdialysis study. Eur J Nucl Med Mol Imaging. 40(10):1582–1594.
   PubMed Web of Science ®Google Scholar
• Ceccarini J, De Hert M, Van Winkel R, Peuskens J, Bormans G, Kranaster L, Enning F, Koethe D, Leweke FM, Van Laere K. 2013. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage. 79:304–312.
   PubMed Web of Science ®Google Scholar
• Cerdá M, Mauro C, Hamilton A, Levy NS, Santaella-Tenorio J, Hasin D, Wall MM, Keyes KM, Martins SS. 2019. Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiatry. 77(2):165–171.
   Web of Science ®Google Scholar
• Chaloupka FJ, Warner KE, Culyer A, Newhouse J. 2000. The economics of smoking. Handbook Health Econ. 1:1539–1627.
   Google Scholar
• Chan GCK, Hall W, Freeman TP, Ferris J, Kelly AB, Winstock A. 2017. User characteristics and effect profile of Butane Hash Oil: An extremely high-potency cannabis concentrate. Drug Alcohol Depend. 178:32–38.
   PubMed Web of Science ®Google Scholar
• Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA. 2019. Feb) New trends in cannabis potency in USA and Europe during the last decade (2008-2017). Eur Arch Psychiatry Clin Neurosci. 269(1):5–15.
   PubMed Web of Science ®Google Scholar
• Chye Y, Kirkham R, Lorenzetti V, McTavish E, Solowij N, Yücel M. 2021. Cannabis, cannabinoids, and brain morphology: a review of the evidence. Biol Psychiatry Cogn Neurosci Neuroimaging. 6(6):627–635.
   PubMedGoogle Scholar
• Clausen L, Hjorthoj CR, Thorup A, Jeppesen P, Petersen L, Bertelsen M, Nordentoft M. 2014. Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial. Psychol Med. 44(1):117–126.
   PubMed Web of Science ®Google Scholar
• Clementz BA, Sweeney JA, Hamm JP, Ivleva EI, Ethridge LE, Pearlson GD, Keshavan MS, Tamminga CA. 2016. Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatry. 173(4):373–384.
   Google Scholar
• Coles AS, Castle D, George TP. 2021. Treatment of cannabis use in schizophrenia and psychosis. In D. C. D'Souza, Castle, D., Murray, R.M. (Ed.). Marijuana and madness (3rd Edition ed., Vol. In Press.). Cambridge: Cambridge University Press.
   Google Scholar
• Colizzi M, Bhattacharyya S. 2017. Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Curr Addict Rep. 4(2):62–74.
   PubMedGoogle Scholar
• Cortes-Briones JA, Cahill JD, Skosnik PD, Mathalon DH, Williams A, Sewell RA, Roach BJ, Ford JM, Ranganathan M, D'Souza DC. 2015. Dec 1) The psychosis-like effects of Δ(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans. Biol Psychiatry. 78(11):805–813.
   PubMed Web of Science ®Google Scholar
• Cortez IL, da Silva NR, Guimarães FS, Gomes FV. 2020. Are CB2 receptors a new target for schizophrenia treatment? Front Psychiatry. 1137.
   PubMed Web of Science ®Google Scholar
• Cupo L, Plitman E, Guma E, Chakravarty MM. 2021. A systematic review of neuroimaging and acute cannabis exposure in age-of-risk for psychosis. Transl Psychiatry. 11(1):1–19.
   PubMed Web of Science ®Google Scholar
• D'Addario C, Micale V, Di Bartolomeo M, Stark T, Pucci M, Sulcova A, Palazzo M, Babinska Z, Cremaschi L, Drago F, et al. 2017. A preliminary study of endocannabinoid system regulation in psychosis: Distinct alterations of CNR1 promoter DNA methylation in patients with schizophrenia. Schizophrenia Res. 188:132–140.
   PubMed Web of Science ®Google Scholar
• D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. 2005. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 57(6):594–608.
   PubMed Web of Science ®Google Scholar
• D'Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin M, et al. 2016. Rapid changes in CB1 receptor availability in cannabis dependent males after abstinence from cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging. 1(1):60–67.
   Google Scholar
• D'Souza DC, Ganesh S, Cortes-Briones J, Campbell MH, Emmanuel MK. 2020. Characterizing psychosis-relevant phenomena and cognitive function in a unique population with isolated, chronic and very heavy cannabis exposure. Psychol Med. 50(14):2452–2459.
   PubMed Web of Science ®Google Scholar
• D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J. 2008. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis [Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.]. Neuropsychopharmacol. 33(10):2505–2516.
   PubMed Web of Science ®Google Scholar
• D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A, et al. 2019. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of annabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel-group, phase 2a single-site randomized trial. Lancet Psychiat. 6(1):35–45.
   PubMed Web of Science ®Google Scholar
• D’Souza DC, Radhakrishnan R, Naganawa M, Ganesh S, Nabulsi N, Najafzadeh S, Ropchan J, Ranganathan M, Cortes-Briones J, Huang Y, et al. 2021. Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. Mol Psychiatry. 26(7):3192–3200.
   PubMed Web of Science ®Google Scholar
• Dalton VS, Long LE, Weickert CS, Zavitsanou K. 2011. Jul) Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Neuropsychopharmacol. 36(8):1620–1630.
   PubMed Web of Science ®Google Scholar
• Davey Smith G, Hemani G. 2014. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 23(R1):R89–R98.
   PubMedGoogle Scholar
• De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. 2003. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2(1):5–9.
   PubMedGoogle Scholar
• Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. 2001. Studies on [3H] CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience. 103(1):9–15.
   PubMed Web of Science ®Google Scholar
• Demontis D, Rajagopal VM, Thorgeirsson TE, Als TD, Grove J, Leppälä K, Gudbjartsson DF, Pallesen J, Hjorthøj C, Reginsson GW, et al. 2019. Genome-wide association study implicates CHRNA2 in cannabis use disorder. Nat Neurosci. 22(7):1066–1074.
   PubMed Web of Science ®Google Scholar
• Deng C, Han M, Huang X-F. 2007. No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neurosci Bull. 23(6):341–347.
   PubMedGoogle Scholar
• Desfossés J, Stip E, Ait Bentaleb L, Lipp O, Chiasson J-P, Furtos A, Venne K, Kouassi E, Potvin S. 2012. Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the “mirror effect” of Schizophrenia. Front Psychiatry. 3:85.
   PubMedGoogle Scholar
• Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, Sirianni M, La Cascia C, Stilo SA, Marques TR, et al. 2012. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry. 72(10):811–816.
   PubMed Web of Science ®Google Scholar
• Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, Bianconi F, Gardner-Sood P, O'Connor J, Russo M, et al. 2015. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2(3):233–238.
   PubMed Web of Science ®Google Scholar
• Di Forti M, Morgan C, Selten J-P, Lynskey M, Murray RM. 2019. High-potency cannabis and incident psychosis: correcting the causal assumption–Authors' reply. Lancet Psychiatry. 6(6):466–467.
   PubMed Web of Science ®Google Scholar
• Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, Rodriguez V, Jongsma HE, Ferraro L, La Cascia C, et al. 2019. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 6(5):427–436.
   PubMed Web of Science ®Google Scholar
• Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, Reis Marques T, Pariante C, et al. 2014. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users [Research Support, Non-U.S. Gov't]. Schizophrenia Bulletin. 40(6):1509–1517.
   PubMed Web of Science ®Google Scholar
• Di Forti M, Wu-Choi B, Quattrone D, Richards AL, Freeman TP, Tripoli G, Gayer-Anderson C, Rodriguez V, Jongsma H, Ferraro L. 2019. The independent and combined influence of schizophrenia polygenic risk score and heavy cannabis use on risk for psychotic disorder: A case-control analysis from the EUGEI study. bioRxiv 844803.
   Google Scholar
• DiNieri JA, Wang X, Szutorisz H, Spano SM, Kaur J, Casaccia P, Dow-Edwards D, Hurd YL. 2011. Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring. Biol Psychiatry. 70(8):763–769.
   PubMed Web of Science ®Google Scholar
• Edwards J, Elkins K, Hinton M, Harrigan SM, Donovan K, Athanasopoulos O, McGorry PD. 2006. Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatr Scand. 114(2):109–117.
   PubMed Web of Science ®Google Scholar
• Eggan SM, Hashimoto T, Lewis DA. 2008. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry. 65(7):772–784.
   PubMed Web of Science ®Google Scholar
• Eggan SM, Stoyak SR, Verrico CD, Lewis DA. 2010. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder. Neuropsychopharmacol. 35(10):2060–2071.
   Google Scholar
• Eldeeb K, Leone-Kabler S, Howlett AC. 2016. CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function. J Basic Clin Physiol Pharmacol. 27(3):311–322.
   Google Scholar
• Elkrief L, Lin B, Marchi M, Afzali MH, Banaschewski T, Bokde ALW, Quinlan EB, Desrivières S, Flor H, Garavan H, et al. 2021. Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood: testing gene × environment moderation and mediation. Psychol Med. :1–11.
   Web of Science ®Google Scholar
• ElSohly M, Gul W. 2014. Constituents of cannabis sativa. In Pertwee R, ed. Handbook of Cannabis (p. 3–22). Oxford University Press.
   Google Scholar
• ElSohly MA, Chandra S, Radwan M, Gon C, Church JC. 2021. A comprehensive review of cannabis potency in the USA in the last decade. Biol Psychiatry Cogn Neurosci Neuroimaging. 6(6):603–606.
   PubMedGoogle Scholar
• Everson EM, Dilley JA, Maher JE, Mack CE. 2019. Post-legalization opening of retail cannabis stores and adult cannabis use in Washington State, 2009-2016. Am J Public Health. 109(9):1294–1301.
   PubMed Web of Science ®Google Scholar
• Fakhoury M. 2017. Role of the endocannabinoid system in the pathophysiology of schizophrenia. Mol Neurobiol. 54(1):768–778.
   PubMed Web of Science ®Google Scholar
• Feingold D, Livne O, Rehm J, Lev-Ran S. 2020. Probability and correlates of transition from cannabis use to DSM-5 cannabis use disorder: results from a large-scale nationally representative study. Drug Alcohol Rev. 39(2):142–151.
   PubMed Web of Science ®Google Scholar
• Finlay DB, Cawston EE, Grimsey NL, Hunter MR, Korde A, Vemuri VK, Makriyannis A, Glass M. 2017. Gαs signalling of the CB1 receptor and the influence of receptor number. Br J Pharmacol. 174(15):2545–2562.
   Google Scholar
• Freeman D, Dunn G, Murray RM, Evans N, Lister R, Antley A, Slater M, Godlewska B, Cornish R, Williams J, et al. 2015. How cannabis causes paranoia: using the intravenous administration of Δ9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull. 41(2):391–399.
   PubMed Web of Science ®Google Scholar
• Freeman TP, Groshkova T, Cunningham A, Sedefov R, Griffiths P, Lynskey MT. 2019. Increasing potency and price of cannabis in Europe, 2006-16. Addiction. 114(6):1015–1023.
   PubMed Web of Science ®Google Scholar
• Gage SH, Jones HJ, Burgess S, Bowden J, Smith GD, Zammit S, Munafò MR. 2017. Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study. Psychol Med. 47(5):971–980.
   PubMed Web of Science ®Google Scholar
• Ganesh S, Cortes-Briones J, Ranganathan M, Radhakrishnan R, Skosnik PD, D’Souza DC. 2020. Psychosis-relevant effects of intravenous delta-9-tetrahydrocannabinol: a mega analysis of individual participant-data from human laboratory studies. Int J Neuropsychopharmacol. 23(9):559–570.
   PubMed Web of Science ®Google Scholar
• Gerra MC, Jayanthi S, Manfredini M, Walther D, Schroeder J, Phillips KA, Cadet JL, Donnini C. 2018. Gene variants and educational attainment in cannabis use: mediating role of DNA methylation. Transl Psychiatry. 8(1):23.
   PubMedGoogle Scholar
• Gillespie NA, Kendler KS. 2021. Use of genetically informed methods to clarify the nature of the association between cannabis use and risk for schizophrenia. JAMA Psychiatry. 78(5):467–468.
   PubMed Web of Science ®Google Scholar
• Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkötter J, Piomelli D. 2004. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 29(11):2108–2114.
   PubMed Web of Science ®Google Scholar
• Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. 2003. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res. 60(1):81–85.
   PubMed Web of Science ®Google Scholar
• Green B, Kavanagh D, Young R. 2003. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev. 22(4):453–460.
   PubMed Web of Science ®Google Scholar
• Grucza RA, Agrawal A, Krauss MJ, Cavazos-Rehg PA, Bierut LJ. 2016. Recent trends in the prevalence of marijuana use and associated disorders in the United States. JAMA Psychiatry. 73(3):300–301.
   PubMed Web of Science ®Google Scholar
• Haddock G, Barrowclough C, Tarrier C, Moring J, O'Brien R, Schofield N, Quinn J, Palmer S, Davies L, Lowens I, et al. 2003. Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial. Br J Psychiatry. 183(5):418–426.
   PubMedGoogle Scholar
• Hall KE, Monte AA, Chang T, Fox J, Brevik C, Vigil DI, Van Dyke M, James KA. 2018. Mental health–related emergency department visits associated with cannabis in Colorado. Acad Emerg Med. 25(5):526–537.
   PubMed Web of Science ®Google Scholar
• Hall W, Lynskey M. 2020. Assessing the public health impacts of legalizing recreational cannabis use: the US experience. World Psychiatry. 19(2):179–186.
   PubMed Web of Science ®Google Scholar
• Hall W, Stjepanović D, Caulkins J, Lynskey M, Leung J, Campbell G, Degenhardt L. 2019. Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. The Lancet. 394(10208):1580–1590.
   PubMed Web of Science ®Google Scholar
• Hartberg CB, Lange EH, Lagerberg TV, Haukvik UK, Andreassen OA, Melle I, Agartz I. 2018. Cortical thickness, cortical surface area and subcortical volumes in schizophrenia and bipolar disorder patients with cannabis use. Eur Neuropsychopharmacol. 28(1):37–47.
   PubMed Web of Science ®Google Scholar
• Hasin DS. 2018. US epidemiology of cannabis use and associated problems. Neuropsychopharmacology. 43(1):195–212.
   PubMed Web of Science ®Google Scholar
• Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, Pickering RP, Ruan WJ, Smith SM, et al. 2015. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry. 72(12):1235–1242.
   PubMed Web of Science ®Google Scholar
• Hasin DS, Wall M, Keyes KM, Cerda M, Schulenberg J, O'Malley PM, Galea S, Pacula R, Feng T. 2015. Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys. Lancet Psychiatry. 2(7):601–608.
   PubMed Web of Science ®Google Scholar
• Henquet C, van Os J, Kuepper R, Delespaul P, Smits M, Campo JA, Myin-Germeys I. 2010. Jun) Psychosis reactivity to cannabis use in daily life: an experience sampling study [Research Support, Non-U.S. Gov't]. Br J Psychiatry. 196(6):447–453.
   PubMed Web of Science ®Google Scholar
• Hindley G, Beck K, Borgan F, Ginestet CE, McCutcheon R, Kleinloog D, Ganesh S, Radhakrishnan R, D'Souza DC, Howes OD. 2020. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry. 7(4):344–353.
   PubMed Web of Science ®Google Scholar
• Hindocha C, Quattrone D, Freeman TP, Murray RM, Mondelli V, Breen G, Curtis C, Morgan CJ, Curran HV, Di Forti M. 2020. Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users? Transl Psychiatry. 10(1):1–13.
   PubMed Web of Science ®Google Scholar
• Hindocha C, Quattrone D, Freeman TP, Murray RM, Mondelli V, Breen G, Curtis C, Morgan CJA, Valerie Curran H, Di Forti M. 2020. May 12) Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users? Transl Psychiatry. 10(1):143.
   PubMed Web of Science ®Google Scholar
• Hirvonen J, Zanotti-Fregonara P, Umhau JC, George DT, Rallis-Frutos D, Lyoo CH, Li CT, Hines CS, Sun H, Terry GE, et al. 2013. Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography. Mol Psychiatry. 18(8):916–921.
   PubMed Web of Science ®Google Scholar
• Hjorthøj C, Larsen MO, Starzer MSK, Nordentoft M. 2021a. Annual incidence of cannabis-induced psychosis, other substance-induced psychoses and dually diagnosed schizophrenia and cannabis use disorder in Denmark from 1994 to 2016. Psychol Med. 51(4):617–622.
   PubMed Web of Science ®Google Scholar
• Hjorthøj C, Posselt CM, Nordentoft M. 2021b. Development over time of the population-attributable risk fraction for cannabis use disorder in schizophrenia in Denmark. JAMA Psychiatry. 78(9):1013–1019.
   PubMed Web of Science ®Google Scholar
• Hjorthøj C, Starzer MSK, Benros ME, Nordentoft M. 2020. Infections as a risk factor for and prognostic factor after substance-induced psychoses. AJP. 177(4):335–341.
   Google Scholar
• Hjorthøj C, Uddin MJ, Hougaard DM, Sørensen HJ, Nordentoft M. 2019. Polygenic risk for psychiatric disorder and singleness in patients with severe mental illness and controls. J Psychiatr Res. 119:60–66.
   PubMed Web of Science ®Google Scholar
• Hjorthøj C, Uddin MJ, Wimberley T, Dalsgaard S, Hougaard DM, Børglum A, Werge T, Nordentoft M. 2021c. No evidence of associations between genetic liability for schizophrenia and development of cannabis use disorder. Psychol Med. 51(3):479–484.
   PubMed Web of Science ®Google Scholar
• Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ. 2015. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 12(4):699–730.
   PubMed Web of Science ®Google Scholar
• James W, Preston NJ, Koh G, Spencer C, Kisely SR, Castle DJ. 2004. A group intervention which assists patients with dual diagnosis reduce their drug use: a randomized controlled trial. Psychol Med. 34(6):983–990.
   PubMed Web of Science ®Google Scholar
• Jenko KJ, Hirvonen J, Henter ID, Anderson KB, Zoghbi SS, Hyde TM, Deep-Soboslay A, Innis RB, Kleinman JE. 2012. Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia. Schizophrenia Research. 141(2–3):185–188.
   PubMed Web of Science ®Google Scholar
• Johnson EC, Demontis D, Thorgeirsson TE, Walters RK, Polimanti R, Hatoum AS, Sanchez-Roige S, Paul SE, Wendt FR, Clarke T-K, et al. 2020. A large-scale genome-wide association study meta-analysis of cannabis use disorder. Lancet Psychiatry. 7(12):1032–1045.
   PubMed Web of Science ®Google Scholar
• Johnson EC, Hatoum AS, Deak JD, Polimanti R, Murray RM, Edenberg HJ, Gelernter J, Di Forti M, Agrawal A. 2021. The relationship between cannabis and schizophrenia: a genetically informed perspective. Addiction. 116(11):3227–3234.
   PubMed Web of Science ®Google Scholar
• Johnston LD, O'Malley PM, Miech RA, Bachman HG, Schulenberg JE. 2016. Monitoring the Future national results on drug use, 1975-2015. Overview, key findings on adolescent drug use. http://www.monitoringthefuture.org/pubs/monographs/mtf-overview2015.pdf.
   Google Scholar
• Jones HJ, Hammerton G, McCloud T, Hines LA, Wright C, Gage SH, Holmans P, Jones PB, Smith GD, Linden DE. 2022. Examining pathways between genetic liability for schizophrenia and patterns of tobacco and cannabis use in adolescence. Psychol Med. 52(1), 132–139.
   Web of Science ®Google Scholar
• Katona I, Freund TF. 2012. Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci. 35:529–558.
   PubMed Web of Science ®Google Scholar
• Kavanagh DAVIDJ, Young ROSS, White ANGELA, Saunders JOHNB, Wallis JEFF, Shockley NATALIE, Jenner LINDA, Clair ANNE. 2004. A brief motivational intervention for substance misuse in recent-onset psychosis. Drug Alcohol Review. 23(2):151–155.
   PubMed Web of Science ®Google Scholar
• Kelley ME, Wan CR, Broussard B, Crisafio A, Cristofaro S, Johnson S, Reed TA, Amar P, Kaslow NJ, Walker EF, et al. 2016. Marijuana use in the immediate 5-year premorbid period is associated with increased risk of onset of schizophrenia and related psychotic disorders. Schizophr Res. 171(1–3):62–67.
   PubMed Web of Science ®Google Scholar
• Kendler KS, Karkowski LM, Neale MC, Prescott CA. 2000. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry. 57(3):261–269.
   PubMed Web of Science ®Google Scholar
• Kendler KS, Ohlsson H, Sundquist J, Sundquist K. 2019. Prediction of onset of substance-induced psychotic disorder and its progression to schizophrenia in a Swedish national sample. AJP. 176(9):711–719.
   Google Scholar
• Kendler KS, Prescott CA. 1998. Cannabis use, abuse, and dependence in a population-based sample of female twins. AJP. 155(8):1016–1022.
   Google Scholar
• Khantzian EJ. 1997. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry. 4(5):231–244.
   PubMed Web of Science ®Google Scholar
• Kittler JT, Grigorenko EV, Clayton C, Zhuang SY, Bundey SC, Trower MM, Wallace D, Hampson R, Deadwyler S. 2000. Large-scale analysis of gene expression changes during acute and chronic exposure to [Delta]9-THC in rats. Physiol Genomics. 3(3):175–185. [pii]
   PubMed Web of Science ®Google Scholar
• Koenders L, Lorenzetti V, de Haan L, Suo C, Vingerhoets W, van den Brink W, Wiers RW, Meijer CJ, Machielsen M, Goudriaan AE, et al. 2017. Longitudinal study of hippocampal volumes in heavy cannabis users. J Psychopharmacol. 31(8):1027–1034.
   PubMed Web of Science ®Google Scholar
• Koenis MMG, Durnez J, Rodrigue AL, Mathias SR, Alexander-Bloch AF, Barrett JA, Doucet GE, Frangou S, Knowles EEM, Mollon J, et al. 2021. Associations of cannabis use disorder with cognition, brain structure, and brain function in African Americans. Hum Brain Mapp. 42(6):1727–1741.
   PubMed Web of Science ®Google Scholar
• Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S, Klosterkotter J, Piomelli D, Leweke FM. 2009a. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis [Comparative Study Research Support, Non-U.S. Gov't]. Br J Psychiatry. 194(4):371–372.
   PubMed Web of Science ®Google Scholar
• Koethe D, Hoyer C, Leweke FM. 2009b. The endocannabinoid system as a target for modelling psychosis. Psychopharmacology. 206(4):551–561.
   PubMed Web of Science ®Google Scholar
• Koethe D, Kranaster L, Hellmich M, Nolden B, Klosterkoetter J. 2009c. Oxcarbazepine as an adjunct of antipsychotic therapy in acute schizophrenia: a double-blind, randomised placebo-controlled clinical trial. Eur Psychiatr. 24(S1):1–1.
   PubMedGoogle Scholar
• Koethe D, Kranaster L, Hoyer C, Gross S, Neatby MA, Schultze-Lutter F, Ruhrmann S, Klosterkötter J, Hellmich M, Leweke FM. 2009d. Binocular depth inversion as a paradigm of reduced visual information processing in prodromal state, antipsychotic-naïve and treated schizophrenia. Eur Arch Psychiatry Clin Neurosci. 259(4):195–202.
   PubMed Web of Science ®Google Scholar
• Koethe D, Llenos I, Dulay J, Hoyer C, Torrey E, Leweke F, Weis S. 2007. Expression of CB 1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm. 114(8):1055–1063.
   PubMed Web of Science ®Google Scholar
• Koethe D, Pahlisch F, Hellmich M, Rohleder C, Mueller JK, Meyer-Lindenberg A, Torrey EF, Piomelli D, Leweke FM. 2019. Familial abnormalities of endocannabinoid signaling in schizophrenia. World J Biol Psychiatry. 20(2):117–125.
   PubMed Web of Science ®Google Scholar
• Kozak, K. B. (2021). Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Cannabis Use and Cognitive Outcomes in Schizophrenia (Doctoral dissertation, University of Toronto (Canada)).
   Google Scholar
• Kraan T, Velthorst E, Koenders L, Zwaart K, Ising HK, van den Berg D, de Haan L, van der Gaag M. 2016. Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis. Psychol Med. 46(4):673–681.
   PubMed Web of Science ®Google Scholar
• Lasebikan V, Aremu OO. 2016. cannabis Use and associated harms among schizophrenia Patients in a Nigerian clinical setting: a case–control study. Front Psychiatry. 7:136.
   PubMed Web of Science ®Google Scholar
• Lauckner JE, Hille B, Mackie K. 2005. The cannabinoid agonist WIN55, 212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci U S A. 102(52):19144–19149.
   Google Scholar
• Leweke FM, Emrich HM. 1999a. Carbamazepine as an adjunct in the treatment of schizophrenia-like psychosis related to cannabis abuse. Int Clin Psychopharmacol. 14(1):37–39.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. 1999b. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 10(8):1665–1669.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Schneider U, Thies M, Münte TF, Emrich HM. 1999c. Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology. 142(3):230–235.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Koethe D, Gerth CW, Nolden BM, Schreiber D, Gross S., … & Klosterkotter, J. (2007). Cannabidiol as an antipsychotic agent. European Psyc. 22(S1), S21–S21.
   Google Scholar
• Leweke F, Koethe D, Gerth C, Nolden B, Schreiber D, Gross S, Kranaster L, Hoyer C, Schultze-Lutter F, Hellmich M. 2007a. Double blind, controlled clinical trial of cannabidiol monotherapy versus amisulpiride in the treatment of acutely psychotic schizophrenia patients. Schizophrenia Bulletin. 33(2), 310–310.
   Web of Science ®Google Scholar
• Leweke F, Koethe D, Gerth C, Nolden B, Schreiber D, Gross S, Schultze-Lutter F, Hellmich M, Klosterkotter J. 2007b. Cannabidiol as an antipsychotic agent. Eur Psychiatry. 22(S1):S21–S21.
   Google Scholar
• Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, Neatby MA, Schneider M, Gerth CW, Hellmich M, et al. 2007c. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophrenia Res. 94(1–3):29–36.
   PubMed Web of Science ®Google Scholar
• Libuy N, de Angel V, Ibáñez C, Murray RM, Mundt AP. 2018. The relative prevalence of schizophrenia among cannabis and cocaine users attending addiction services. Schizophrenia Res. 194:13–17.
   PubMed Web of Science ®Google Scholar
• Lorenzetti V, Chye Y, Silva P, Solowij N, Roberts CA. 2019. Does regular cannabis use affect neuroanatomy? An updated systematic review and meta-analysis of structural neuroimaging studies. Eur Arch Psychiatry Clin Neurosci. 269(1):59–71.
   PubMed Web of Science ®Google Scholar
• Lu HC, Mackie K. 2016. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 79(7):516–525.
   PubMed Web of Science ®Google Scholar
• Lynskey MT, Heath A, Nelson E, Bucholz K, Madden P, Slutske W, Statham D, Martin N. 2002. Genetic and environmental contributions to cannabis dependence in a national young adult twin sample. Psychol Med. 32(2):195–207.
   PubMed Web of Science ®Google Scholar
• Machielsen M, Beduin AS, Dekker N. 2012. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J. Psychopharmacol. 26(1):89–95.
   Web of Science ®Google Scholar
• Mackey S, Allgaier N, Chaarani B, Spechler P, Orr C, Bunn J, Allen NB, Alia-Klein N, Batalla A, Blaine S, et al. 2019. Mega-analysis of gray matter volume in substance dependence: general and substance-specific regional effects. AJP. 176(2):119–128.
   Google Scholar
• Maloney-Hall B, Wallingford SC, Konefal S, Young MM. 2020. Jun) Psychotic disorder and cannabis use: Canadian hospitalization trends, 2006-2015. Health Promot Chronic Dis Prev Can. 40(5–6):176–183.
   PubMed Web of Science ®Google Scholar
• Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. 2016. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 42(5):1262–1269.
   PubMed Web of Science ®Google Scholar
• McHugh MJ, McGorry PD, Yung AR, Lin A, Wood SJ, Hartmann JA, Nelson B. 2017. Cannabis-induced attenuated psychotic symptoms: implications for prognosis in young people at ultra-high risk for psychosis. Psychol Med. 47(4):616–626.
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Parker LA. 2013. The endocannabinoid system and the brain. Annu Rev Psychol. 64:21–47.
   PubMed Web of Science ®Google Scholar
• Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. 2007. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 370(9584):319–328.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Freeman T, Powell J, Curran HV. 2016. AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. Transl Psychiatry. 6(2):e738–e738.
   PubMed Web of Science ®Google Scholar
• Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV. 2018. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Transl Psychiatry. 8(1):181.
   PubMedGoogle Scholar
• Muguruza C, Lehtonen M, Aaltonen N, Morentin B, Meana JJ, Callado LF. 2013. Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. Schizophrenia Res. 148(1–3):145–150.
   PubMed Web of Science ®Google Scholar
• Muguruza C, Morentin B, Meana JJ, Alexander SP, Callado LF. 2019. Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia. J Psychopharmacol. 33(9):1132–1140.
   PubMed Web of Science ®Google Scholar
• Murrie B, Lappin J, Large M, Sara G. 2020. Transition of substance-induced, brief, and atypical psychoses to schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 46(3):505–516.
   PubMed Web of Science ®Google Scholar
• Mustonen A, Niemela S, Nordstrom T, Murray GK, Maki P, Jaaskelainen E, Miettunen J. 2018. Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis. Br J Psychiatry. 212(4):227–233.
   PubMed Web of Science ®Google Scholar
• Myles H, Myles N, Large M. 2016. Cannabis use in first episode psychosis: meta-analysis of prevalence, and the time course of initiation and continued use. Aust NZ J Psychiatry. 50(3):208–219.
   PubMed Web of Science ®Google Scholar
• Neilson E, Bois C, Gibson J, Duff B, Watson A, Roberts N, Brandon NJ, Dunlop J, Hall J, McIntosh AM, et al. 2017. Effects of environmental risks and polygenic loading for schizophrenia on cortical thickness. Schizophr Res. 184:128–136.
   PubMed Web of Science ®Google Scholar
• Newell KA, Deng C, Huang X-F. 2006. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res. 172(4):556–560.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Toftdahl N, Nordentoft M, Hjorthøj C. 2017. Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: a nationwide population based register study. Psychol Med. 47(9):1668–1677.
   PubMed Web of Science ®Google Scholar
• Niemi-Pynttari JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. 2013. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry. 74(01):e94-99–e99.
   Google Scholar
• Niesink RJ, van Laar MW. 2013. Does cannabidiol protect against adverse psychological effects of THC? Front Psychiatry. 4:130.
   PubMedGoogle Scholar
• Orr C, Spechler P, Cao Z, Albaugh M, Chaarani B, Mackey S, D'Souza D, Allgaier N, Banaschewski T, Bokde ALW, et al. 2019. Grey matter volume differences associated with extremely low levels of cannabis use in adolescence. J Neurosci. 39(10):1817–1827.
   PubMed Web of Science ®Google Scholar
• Osborne AJ, Pearson JF, Noble AJ, Gemmell NJ, Horwood LJ, Boden JM, Benton MC, Macartney-Coxson DP, Kennedy MA. 2020. Apr 22) Genome-wide DNA methylation analysis of heavy cannabis exposure in a New Zealand longitudinal cohort. Transl Psychiatry. 10(1):114.
   PubMed Web of Science ®Google Scholar
• Pacula RL, Kilmer B, Wagenaar AC, Chaloupka FJ, Caulkins JP. 2014. Developing public health regulations for marijuana: lessons from alcohol and tobacco. Am J Public Health. 104(6):1021–1028.
   PubMed Web of Science ®Google Scholar
• Parmentier-Batteur S, Jin K, Xie L, Mao XO, Greenberg DA. 2002. DNA microarray analysis of cannabinoid signaling in mouse brain in vivo. Mol Pharmacol. 62(4):828–835.
   PubMed Web of Science ®Google Scholar
• Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, Abdellaoui A, Nivard MG, Baselmans BML, Ong J-S, et al. 2018. GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability. Nat Neurosci. 21(9):1161–1170.
   PubMed Web of Science ®Google Scholar
• Peters BD, de Koning P, Dingemans P, Becker H, Linszen DH, de Haan L. 2009. Subjective effects of cannabis before the first psychotic episode. Aust NZ J Psychiatry. 43(12):1155–1162.
   PubMed Web of Science ®Google Scholar
• Potvin S, Kouassi É, Lipp O, Bouchard R-H, Roy M-A, Demers M-F, Gendron A, Astarita G, Piomelli D, Stip E. 2008. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol. 22(3):262–269.
   PubMed Web of Science ®Google Scholar
• Potvin S, Stip E, Lipp O, Élie R, Mancini-Marië A, Demers M-F, Roy M-A, Bouchard R-H, Gendron A. 2006. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin. 22(7):1277–1285.
   PubMed Web of Science ®Google Scholar
• Power RA, Verweij KJ, Zuhair M, Montgomery GW, Henders AK, Heath AC, Madden PA, Medland SE, Wray NR, Martin NG. 2014. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry. 19(11):1201–1204.
   PubMed Web of Science ®Google Scholar
• Prini P, Rusconi F, Zamberletti E, Gabaglio M, Penna F, Fasano M, Battaglioli E, Parolaro D, Rubino T. 2018. Adolescent THC exposure in female rats leads to cognitive deficits through a mechanism involving chromatin modifications in the prefrontal cortex. JPN. 43(2):87–101.
   Google Scholar
• Quinn M, McHugo M, Armstrong K, Woodward N, Blackford J, Heckers S. 2018. Impact of substance use disorder on gray matter volume in schizophrenia. Psychiatry Res Neuroimaging. 280:9–14.
   PubMed Web of Science ®Google Scholar
• Rabin RA, Barr MS, Goodman MS, Herman Y, Zakzanis KK, Kish SJ, Kiang M, Remington G, George TP. 2017. Effects of extended cannabis abstinence on neurocognitive outcomes in cannabis dependent schizophrenia patients versus non-psychiatric controls. Neuropsychopharmacol. 42(11):2259–2271.
   PubMed Web of Science ®Google Scholar
• Rabin RA, Kozak K, Zakzanis KK, Remington G, Stefan C, Budney AJ, George TP. 2018a. A method to achieve short-term cannabis abstinence in cannabis-dependent patients with schizophrenia and non-psychiatric controls. Schizophr Res. 194:47–54.
   PubMed Web of Science ®Google Scholar
• Rabin RA, Kozak K, Zakzanis KK, Remington G, George TP. 2018b. Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. Schizophr Res. 194:55–61.
   PubMed Web of Science ®Google Scholar
• Rais M, van Haren NE, Cahn W, Schnack HG, Lepage C, Collins L, Evans AC, Hulshoff Pol HE, Kahn RS. 2010. Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. European Neuropsychopharmacology. 20(12):855–865.
   PubMed Web of Science ®Google Scholar
• Ranganathan M, Cortes-Briones J, Radhakrishnan R, Thurnauer H, Planeta B, Skosnik P, Gao H, Labaree D, Neumeister A, Pittman B, et al. 2016. Reduced brain cannabinoid receptor availability in schizophrenia. Biol Psychiatry. 79(12):997–1005.
   PubMed Web of Science ®Google Scholar
• Reuter AR, Bumb JM, Mueller JK, Rohleder C, Pahlisch F, Hanke F, Arens E, Leweke FM, Koethe D, Schwarz E. 2017. Association of anandamide with altered binocular depth inversion illusion in schizophrenia. World J Biol Psychiatry. 18(6):483–488.
   PubMed Web of Science ®Google Scholar
• Ripke S, Neale BM, Corvin A, Walters JT, Farh K-H, Holmans PA, Lee P, Bulik-Sullivan B, Collier DA, Huang H. 2014. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 511(7510):421.
   PubMed Web of Science ®Google Scholar
• Rømer Thomsen K, Lindholst C, Thylstrup B, Kvamme S, Reitzel LA, Worm-Leonhard M, Englund A, Freeman TP, Hesse M. 2019. Changes in the composition of cannabis from 2000-2017 in Denmark: analysis of confiscated samples of cannabis resin. Exp Clin Psychopharmacol. 27(4):402–411.
   PubMed Web of Science ®Google Scholar
• Rubino T, Parolaro D. 2016. The impact of exposure to cannabinoids in adolescence: insights from animal models. Biol Psychiatry. 79(7):578–585.
   PubMed Web of Science ®Google Scholar
• Ryan JE, Veliz P, McCabe SE, Stoddard SA, Boyd CJ. 2020. Association of early onset of cannabis, cigarette, other drug use and schizophrenia or psychosis. Schizophr Res. 215:482–484.
   PubMed Web of Science ®Google Scholar
• Salloum NC, Krauss MJ, Agrawal A, Bierut LJ, Grucza RA. 2018. A reciprocal effects analysis of cannabis use and perceptions of risk. Addiction. 113(6):1077–1085.
   PubMed Web of Science ®Google Scholar
• Sami M, Cole JH, Kempton MJ, Annibale L, Das D, Kelbrick M, Eranti S, Collier T, Onyejiaka C, O'Neill A, et al. 2020. Cannabis use in patients with early psychosis is associated with alterations in putamen and thalamic shape. Hum Brain Mapp. 41(15):4386–4396.
   PubMed Web of Science ®Google Scholar
• Schnell T, Koethe D, Krasnianski A, Gairing S, Schnell K, Daumann J, Gouzoulis-Mayfrank E. 2014. Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. Am J Addict. 23(3):308–312.
   PubMed Web of Science ®Google Scholar
• Schoeler T, Monk A, Sami MB, Klamerus E, Foglia E, Brown R, Camuri G, Altamura AC, Murray R, Bhattacharyya S. 2016. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry. 3(3):215–225.
   PubMed Web of Science ®Google Scholar
• Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Ajnakina O, Gayer-Anderson C, Colizzi M, Quattrone D, Behlke I, et al. 2016. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry. 3(10):947–953.
   PubMed Web of Science ®Google Scholar
• Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Murray R, Bhattacharyya S. 2017. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. Lancet Psychiatry. 4(8):627–633.
   PubMed Web of Science ®Google Scholar
• Schoeler T, Petros N, Di Forti M, Pingault JB, Klamerus E, Foglia E, Small A, Murray R, Bhattacharyya S. 2016. Association between continued cannabis use and risk of relapse in first-episode psychosis: a quasi-experimental investigation within an observational study. JAMA Psychiatry. 73(11):1173–1179.
   PubMed Web of Science ®Google Scholar
• Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP. 2011a. Cannabis with high cannabidiol content is associated with fewer psychotic experiences [Research Support, Non-U.S. Gov't]. Schizophrenia Res. 130(1–3):216–221.
   PubMed Web of Science ®Google Scholar
• Schubart CD, van Gastel WA, Breetvelt EJ, Beetz SL, Ophoff RA, Sommer IE, Kahn RS, Boks MP. 2011b. Cannabis use at a young age is associated with psychotic experiences. Psychol Med. 41(6):1301–1310.
   PubMed Web of Science ®Google Scholar
• Shakoor S, Zavos HM, McGuire P, Cardno AG, Freeman D, Ronald A. 2015. Psychotic experiences are linked to cannabis use in adolescents in the community because of common underlying environmental risk factors. Psychiatry Res. 227(2–3):144–151.
   PubMed Web of Science ®Google Scholar
• Sherif M, Radhakrishnan R, D'Souza DC, Ranganathan M. 2016. Human laboratory studies on cannabinoids and psychosis. Biol Psychiatry. 79(7):526–538.
   PubMed Web of Science ®Google Scholar
• Sigmon SC, Higgins ST. 2006. Voucher-based contingent reinforcement of marijuana abstinence among individuals with serious mental illness. J Subst Abuse Treat. 30(4):291–295.
   PubMed Web of Science ®Google Scholar
• Sigmon SC, Steingard S, Badger GJ, Anthony SL, Higgins ST. 2000. Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: a feasibility study. Exp Clin Psychopharmacol. 8(4):509–517.
   PubMed Web of Science ®Google Scholar
• Slavet JD, Stein LAR, Colby SM, Barnett NP, Monti PM, Golembeske C, Lebeau-Craven R. 2006. The Marijuana Ladder: measuring motivation to change marijuana use in incarcerated adolescents. Drug Alcohol Depend. 83(1):42–48.
   PubMed Web of Science ®Google Scholar
• Smart R, Caulkins JP, Kilmer B, Davenport S, Midgette G. 2017. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction. 112(12):2167–2177.
   PubMed Web of Science ®Google Scholar
• Smith A, Kaufman F, Sandy MS, Cardenas A. 2020. Cannabis exposure during critical windows of development: epigenetic and molecular pathways implicated in neuropsychiatric disease. Curr Environ Health Rep. 7(3):325–342.
   PubMedGoogle Scholar
• Sobell LC, Cunningham JA, Sobell MB, Agrawal S, Gavin DR, Leo GI, Singh KN. 1996. Fostering self-change amongst problem drinkers: a proactive community intervention. Addict. Behav. 21(6):817–833.
   PubMed Web of Science ®Google Scholar
• Solowij N, Yücel M, Respondek C, Whittle S, Lindsay E, Pantelis C, Lubman D. 2011. Cerebellar white-matter changes in cannabis users with and without schizophrenia. Psychol Med. 41(11):2349–2359.
   PubMed Web of Science ®Google Scholar
• Spindle TR, Bonn-Miller MO, Vandrey R. 2019. Changing landscape of cannabis: novel products, formulations, and methods of administration. Curr Opin Psychol. 30:98–102.
   PubMed Web of Science ®Google Scholar
• Starzer MSK, Nordentoft M, Hjorthøj C. 2018. Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. Am J Psychiatry. 175(4):343–350.
   PubMed Web of Science ®Google Scholar
• Stilo SA, Murray RM. 2019. Non-genetic factors in schizophrenia. Curr Psychiatry Rep. 21(10):1–10.
   PubMed Web of Science ®Google Scholar
• Stirling J, Barkus EJ, Nabosi L, Irshad S, Roemer G, Schreudergoidheijt B, Lewis S. 2008. Cannabis-induced psychotic-like experiences are predicted by high schizotypy. Confirmation of preliminary results in a large cohort. Psychopathology. 41(6):371–378.
   PubMedGoogle Scholar
• Stoychev KR. 2019. Neuroimaging studies in patients with mental disorder and co-occurring substance use disorder: summary of findings. Front Psychiatry. 10:702.
   PubMed Web of Science ®Google Scholar
• Szutorisz H, Egervári G, Sperry J, Carter JM, Hurd YL. 2016. Cross-generational THC exposure alters the developmental sensitivity of ventral and dorsal striatal gene expression in male and female offspring. Neurotoxicol Teratol. 58:107–114.
   PubMed Web of Science ®Google Scholar
• Szutorisz H, Hurd YL. 2016. Epigenetic effects of cannabis exposure. Biol Psychiatry. 79(7):586–594.
   PubMed Web of Science ®Google Scholar
• Tamminga CA, Pearlson GD, Stan AD, Gibbons RD, Padmanabhan J, Keshavan M, Clementz BA. 2017. Strategies for advancing disease definition using biomarkers and genetics: the bipolar and schizophrenia network for intermediate phenotypes. Biol Psychiatry Cogn Neurosci Neuroimaging. 2(1):20–27.
   Google Scholar
• Tang SM, Ansarian A, Courtney DB. 2017. Clozapine treatment and cannabis use in adolescents with psychotic disorders – a retrospective cohort chart review. J Can Acad Child Adolesc Psychiatry. 26(1):51–58.
   PubMed Web of Science ®Google Scholar
• Urigüen L, García-Fuster MJ, Callado LF, Morentin B, La Harpe R, Casadó V, Lluis C, Franco R, García-Sevilla JA, Meana JJ. 2009. Immunodensity and mRNA expression of A 2A adenosine, D 2 dopamine, and CB 1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology. 206(2):313–324.
   PubMed Web of Science ®Google Scholar
• Vadhan NP, Corcoran CM, Bedi G, Keilp JG, Haney M. 2017. Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: a preliminary study. Psychiatry Res. 257:372–374.
   PubMed Web of Science ®Google Scholar
• van der Meer FJ, Velthorst E, Genetic R, Outcome Of Psychosis I. 2015. Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study. Psychol Med. 45(9):1977–1988.
   PubMed Web of Science ®Google Scholar
• van Os J, Pries LK, Ten Have M, de Graaf R, van Dorsselaer S, Bak M, Wittchen HU, Rutten BPF, Guloksuz S. 2021. Schizophrenia and the environment: within-person analyses may be required to yield evidence of unconfounded and causal association-the example of cannabis and psychosis. Schizophr Bull. 47(3):594–603.
   PubMed Web of Science ®Google Scholar
• van Winkel R, Risk G, Investigators OoP. 2011. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry. 68(2):148–157.
   PubMed Web of Science ®Google Scholar
• Vaucher J, Keating BJ, Lasserre AM, Gan W, Lyall DM, Ward J, Smith DJ, Pell JP, Sattar N, Paré G, et al. 2018. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol Psychiatry. 23(5):1287–1292.
   PubMed Web of Science ®Google Scholar
• Volk DW, Eggan SM, Horti AG, Wong DF, Lewis DA. 2014. Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia [Research Support, N.I.H., Extramural]. Schizophrenia Research. 159(1):124–129.
   PubMed Web of Science ®Google Scholar
• Wainberg M, Jacobs GR, di Forti M, Tripathy SJ. 2021. Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank. Transl Psychiatry. 11(1):211.
   PubMed Web of Science ®Google Scholar
• Wainberg M, Jacobs GR, di Forti M, Tripathy SJ. 2021. Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank. Transl Psychiatry. 11(1):1–9.
   PubMed Web of Science ®Google Scholar
• Wang GS, Davies SD, Halmo LS, Sass A, Mistry RD. 2018. Impact of marijuana legalization in Colorado on adolescent emergency and urgent care visits. J Adolesc Health. 63(2):239–241.
   PubMed Web of Science ®Google Scholar
• Wang GS, Hall K, Vigil D, Banerji S, Monte A, VanDyke M. 2017. Marijuana and acute health care contacts in Colorado. Prev Med. 104:24–30.
   PubMed Web of Science ®Google Scholar
• Wang GS, Hoyte C. 2018. Common substances of abuse. Pediatr Rev. 39(8):403–414.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zuo C, Xu Q, Hao L. 2021. Cerebellar thickness changes associated with heavy cannabis use: a 3-year longitudinal study. Addict Biol. 26(3):e12931.
   PubMed Web of Science ®Google Scholar
• Watson CT, Szutorisz H, Garg P, Martin Q, Landry JA, Sharp AJ, Y. L H. 2015. Genome-wide DNA methylation profiling reveals epigenetic changes in the rat nucleus accumbens associated with cross-generational effects of adolescent THC exposure. Neuropsychopharmacology. 40(13):2993–3005.
   PubMed Web of Science ®Google Scholar
• Watts JJ, Jacobson MR, Lalang N, Boileau I, Tyndale RF, Kiang M, Ross RA, Houle S, Wilson AA, Rusjan P, et al. 2020. Imaging brain fatty acid amide hydrolase in untreated patients with psychosis. Biol Psychiatry. 88(9):727–735.
   PubMed Web of Science ®Google Scholar
• Wojtalik JA, Hogarty SS, Cornelius JR, Phillips ML, Keshavan MS, Newhill CE, Eack SM. 2015. Cognitive Enhancement therapy improves frontolimbic regulation of emotion in alcohol and/or cannabis misusing schizophrenia: a preliminary study. Front Psychiatry. 6:186.
   PubMed Web of Science ®Google Scholar
• Wong DF, Kuwabara H, Horti AG, Raymont V, Brasic J, Guevara M, Ye W, Dannals RF, Ravert HT, Nandi A, et al. 2010. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C] OMAR. Neuroimage. 52(4):1505–1513.
   PubMed Web of Science ®Google Scholar
• Yu Y, Li Y, Li T, Xi S, Xiao X, Xiao S, Tebes JK. 2020. New path to recovery and well-being: cross-sectional study on Wechat use and endorsement of Wechat-based mHealth among people living with schizophrenia in China. J Med Internet Res. 22(9):e18663.
   PubMed Web of Science ®Google Scholar
• Yücel M, Lorenzetti V, Suo C, Zalesky A, Fornito A, Takagi MJ, Lubman D, Solowij N. 2016. Hippocampal harms, protection and recovery following regular cannabis use. Transl Psychiatry. 6(1):e710.
   PubMedGoogle Scholar
• Zammit S, Spurlock G, Williams H, Norton N, Williams N, O'Donovan MC, Owen MJ. 2007. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry. 191(5):402–407.
   PubMedGoogle Scholar
• Zavitsanou K, Garrick T, Huang XF. 2004. Selective antagonist [3H] SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 28(2):355–360.
   PubMed Web of Science ®Google Scholar
• Zyromski NJ, Mathur A, Pitt HA, Wade TE, Wang S, Swartz-Basile DA, Prather AD, Lillemoe KD. 2009. Cannabinoid receptor-1 blockade attenuates acute pancreatitis in obesity by an adiponectin mediated mechanism. J Gastrointest Surg. 13(5):831–838.
   PubMed Web of Science ®Google Scholar